Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effectiveness of Voxelotor for Treating Sickle Cell Disease

X
Trial Profile

Effectiveness of Voxelotor for Treating Sickle Cell Disease

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Voxelotor (Primary)
  • Indications Sickle cell anaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Dec 2022 Results (n=4023) evaluating rates of transfusions, vaso-occlusive crises, and hospitalizations among patients with SCD, including pediatric patients, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
    • 14 Dec 2021 Results (As of March 2021, n=2695 )presented at the 63rd American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2021 Results (n=3128) presented in Global Blood Therapeutics media released.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top